However, JAK inhibitors suppress the MPN clone and mutation load only partially, whereas IFN-α2 therapy leads to durable clinical and hematological remission for >75% MPN patients, as well as molecular remission for ~10% JAK2V617F-mutated PV, ET and PMF patients (33, 37, 46–48). This evidence concerns the gene IFNA2 and myeloproliferative disorder.